The global Janus Kinase (JAK) Inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). JAK inhibitors are an oral class of therapeutics that are gaining traction owing to an increase in the number of Immune-Mediated Inflammatory Diseases (IMIDs) treatments across the globe. JAK consists of four intracellular non-receptor tyrosine kinases that enable cytokine-mediated signalling through the JAK-STAT pathway. It contains two nearly identical phosphate-transferring domains, in which one domain shows kinase activity and the other regulates the activity of the first via negative inhibition. The four receptors in the JAK family are JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). The mutation in any of these can lead to various medical conditions.
To Request a Sample of our Report on Global Janus Kinase (JAK) Inhibitors Therapy Market: https://www.omrglobal.com/request-sample/janus-kinase-jak-inhibitors-therapy-market
Clinical results of JAK inhibitors promise patients effective and more convenient treatment options in multiple indications when compared to the traditional treatments approach. The first of them to enter the market, with approval for Rheumatoid Arthritis (RA), were tofacitinib (now also approved for Psoriatic Arthritis and Ulcerative Colitis) and baricitinib, followed by upadacitinib (RA). Moreover, with the increasing prevalence of arthritis across the globe, the global market for JAK inhibitors is also expected to witness a rapid pace. According to the Arthritis Foundation, arthritis affects more than 1 in 4 adults. Moreover, by 2040, the number of adults in the US with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million (25.9% of all adults). The number of adults reporting activity limitations due to their arthritis will increase 52% to 34.6 million (11.4% of all adults).
Some key players operating in the market include Eli Lilly, Astellas, Pfizer, Baxter, Novartis, Abbvie, Sierra Oncology, CTI BioPharma, and Incyte and others. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Eli Lilly, Astellas, Pfizer, Baxter, Novartis, Abbvie, Sierra Oncology, CTI BioPharma, and Incyte and others.
A full Report of Global Janus Kinase (JAK) Inhibitors Therapy Market is Available @ https://www.omrglobal.com/industry-reports/janus-kinase-jak-inhibitors-therapy-market
Global Janus Kinase (JAK) Inhibitors Therapy Market by Segment
By Application
- Autoimmune Disorders
- Oncology
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Janus Kinase (JAK) Inhibitors Therapy Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/janus-kinase-jak-inhibitors-therapy-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
